Virpax Pharmaceuticals (VRPX) Competitors $0.24 -0.02 (-8.27%) As of 06/12/2025 03:47 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRPX vs. CWBR, EVFM, TRVN, PTPI, NMTR, SYRS, REVB, SRNE, ATXI, and BIORShould you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include CohBar (CWBR), Evofem Biosciences (EVFM), Trevena (TRVN), Petros Pharmaceuticals (PTPI), 9 Meters Biopharma (NMTR), Syros Pharmaceuticals (SYRS), Revelation Biosciences (REVB), Sorrento Therapeutics (SRNE), Avenue Therapeutics (ATXI), and Biora Therapeutics (BIOR). These companies are all part of the "pharmaceutical products" industry. Virpax Pharmaceuticals vs. Its Competitors CohBar Evofem Biosciences Trevena Petros Pharmaceuticals 9 Meters Biopharma Syros Pharmaceuticals Revelation Biosciences Sorrento Therapeutics Avenue Therapeutics Biora Therapeutics CohBar (NASDAQ:CWBR) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment. Does the MarketBeat Community favor CWBR or VRPX? CohBar received 15 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. Likewise, 72.00% of users gave CohBar an outperform vote while only 60.00% of users gave Virpax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCohBarOutperform Votes1872.00% Underperform Votes728.00% Virpax PharmaceuticalsOutperform Votes360.00% Underperform Votes240.00% Do analysts prefer CWBR or VRPX? Virpax Pharmaceuticals has a consensus price target of $75.00, suggesting a potential upside of 31,333.36%. Given Virpax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Virpax Pharmaceuticals is more favorable than CohBar.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CohBar 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger valuation & earnings, CWBR or VRPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCohBarN/AN/A-$12.18MN/AN/AVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/A Does the media favor CWBR or VRPX? In the previous week, CohBar's average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score. Company Overall Sentiment CohBar Neutral Virpax Pharmaceuticals Neutral Which has more volatility and risk, CWBR or VRPX? CohBar has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Do insiders & institutionals believe in CWBR or VRPX? 2.5% of CohBar shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 6.5% of CohBar shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is CWBR or VRPX more profitable? CohBar's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets CohBarN/A N/A N/A Virpax Pharmaceuticals N/A -1,554.34%-338.29% SummaryCohBar beats Virpax Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRPX vs. The Competition Export to ExcelMetricVirpax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$296K$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E RatioN/A8.6727.1419.96Price / SalesN/A262.53416.49157.63Price / CashN/A65.8538.2534.64Price / Book0.146.597.074.69Net Income-$15.19M$143.75M$3.23B$248.14M7 Day Performance-2.41%0.68%0.72%0.91%1 Month Performance-11.89%11.93%9.65%5.71%1 Year Performance-98.64%4.33%32.02%14.71% Virpax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRPXVirpax Pharmaceuticals1.5462 of 5 stars$0.24-8.3%$75.00+31,333.4%-98.7%$296KN/A0.007CWBRCohBarN/A$0.41flatN/AN/A$1.19MN/A0.0010EVFMEvofem Biosciences0.8231 of 5 stars$0.01+10.0%N/A-24.2%$1.18M$11.39M-0.02120Short Interest ↑Gap UpTRVNTrevena1.7893 of 5 stars$1.15+2.2%$5.00+334.8%-89.8%$1.10M$443K-0.0240Gap UpPTPIPetros Pharmaceuticals0.4059 of 5 stars$0.03-4.2%N/A-99.7%$1.08M$5.11M-0.0120Positive NewsShort Interest ↑Gap DownNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220SYRSSyros Pharmaceuticals3.7561 of 5 stars$0.03+6.7%$3.33+10,316.7%-99.6%$859K$386K-0.01120Gap DownREVBRevelation Biosciences0.4523 of 5 stars$0.82-3.2%N/A-97.8%$819KN/A0.0010Short Interest ↑High Trading VolumeSRNESorrento Therapeutics0.3522 of 5 stars$0.00-23.5%N/A-83.8%$717K$60.32M0.00800Gap DownATXIAvenue Therapeutics1.8562 of 5 stars$0.25+14.7%N/A-91.9%$694KN/A0.014Gap DownBIORBiora Therapeutics1.7991 of 5 stars$0.14-1.4%$23.00+16,328.6%-98.1%$633K$892K-0.01120Upcoming Earnings Related Companies and Tools Related Companies CWBR Alternatives EVFM Alternatives TRVN Alternatives PTPI Alternatives NMTR Alternatives SYRS Alternatives REVB Alternatives SRNE Alternatives ATXI Alternatives BIOR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRPX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
